Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan Apr 20, 2023 08:00AM
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma Oct 14, 2021 08:00AM
Exelixis (EXEL) In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational NDA for Phase 1 Clinical Trial in Advanced Solid Tumors Dec 7, 2020 08:08AM
Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors Dec 7, 2020 08:00AM
Exelixis (EXEL) and Aurigene Announce Promising Preclinical Data to Be Presented at ENA Symposium Support Clinical Development of Novel CDK7 Inhibitor Oct 9, 2020 06:09AM


Oct 9, 2020 03:02AM Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
Sep 23, 2020 09:04AM Global Response Aid and Dr. Reddy's Laboratories (RDY) Announces Avigan Shows Promising Results in Treatment of COVID Patients in Japan
Sep 23, 2020 09:01AM Avigan® Shows Promising Results in Treatment of COVID Patients in Japan
Jul 31, 2019 04:05PM Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
Mar 16, 2017 07:00AM CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy's Laboratories
Nov 9, 2015 07:22PM SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Dr. Reddy’s Laboratories Ltd. and Strongly Encourages Investors to Contact the Firm
Apr 1, 2015 06:52AM Dr. Reddy’s Laboratories to Acquire Select Portfolio of the Established Products Business of UCB in India